Jazz, PharmaMar get FDA accelerated approval for Zepzelca in metastatic SCLC

This article was originally published here

The approval of Zepzelca is for treating metastatic small cell lung cancer in adults whose disease has progressed on or after platinum-based chemotherapy. The alkylating drug, which is

The post Jazz, PharmaMar get FDA accelerated approval for Zepzelca in metastatic SCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply